{
  "ticker": "JNJ",
  "target_date": "2025-09-11",
  "actual_date": "2025-09-11",
  "collected_at": "2025-12-08T12:16:08.114471",
  "price": {
    "open": 174.64,
    "high": 177.72,
    "low": 174.52,
    "close": 177.37380981445312,
    "volume": 5792500,
    "change_1d_pct": 1.54,
    "change_7d_pct": 0.25,
    "change_30d_pct": 7.5
  },
  "technicals": {
    "rsi_14": 53.47,
    "sma_20": 175.84,
    "sma_50": 167.96,
    "macd": 2.336,
    "macd_signal": 2.881,
    "macd_histogram": -0.545,
    "bb_upper": 178.58,
    "bb_lower": 173.09,
    "price_vs_sma20_pct": 0.87,
    "price_vs_sma50_pct": 5.61,
    "volume_ratio": 0.73
  },
  "fundamentals": {
    "market_cap": 487701577728,
    "pe_ratio": 19.539093,
    "forward_pe": 19.096697,
    "price_to_book": 6.143959,
    "price_to_sales": 5.2925324,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.59,
    "pct_from_52w_low": 43.89
  },
  "macro": {
    "spy": {
      "price": 655.81,
      "change_1d_pct": 0.83,
      "change_7d_pct": 2.16
    },
    "vix": {
      "level": 14.71,
      "signal": "LOW_FEAR"
    },
    "treasury_10y": {
      "yield_pct": 4.01
    },
    "dollar_index": {
      "level": 97.54
    },
    "gold": {
      "price": 3636.9
    },
    "regime": "BULL_LOW_VOL"
  },
  "news": [
    {
      "headline": "Johnson & Johnson (JNJ) Surpasses Market Returns: Some Facts Worth Knowing",
      "source": "Yahoo",
      "datetime": 1757630704,
      "summary": "In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $178.41, denoting a +1.49% move from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=7034b1ce1d13c1889bbc401a66106621a9acbcb3c9280839a39cd3304fcc82f4"
    },
    {
      "headline": "Prescription Drug Ads Face Big Changes. These Stocks Could Get Hurt the Most.",
      "source": "Yahoo",
      "datetime": 1757626800,
      "summary": "Big changes could be coming to pharmaceutical advertising on TV, potentially causing problems for the broadcasters and networks that get paid to host those commercials.  TV watchers have become all too familiar with seeing prescription drug ads while watching their favorite programs.  Hearing person",
      "url": "https://finnhub.io/api/news?id=ef031a64d1e0048d78b962fb09dfc743fa82b51b16d70e2c3d958543cd04d7e3"
    },
    {
      "headline": "Warren Buffett wouldn\u2019t worry about cash if he retired with just $1M \u2014 here\u2019s why and how to copy his strategy",
      "source": "Yahoo",
      "datetime": 1757615400,
      "summary": "Here's how you could copy the Oracle of Omaha in today's market.",
      "url": "https://finnhub.io/api/news?id=095d10f7cb6df7f5f226156f606f2be2d05e5929b36881079bec4fc69345824f"
    },
    {
      "headline": "Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know",
      "source": "Yahoo",
      "datetime": 1757599205,
      "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=770fd8036a3d40edd60e8eedb6b4ef88b4dbde8ba4b6f690c214cce3f9d75e09"
    },
    {
      "headline": "Johnson & Johnson seeks first European Medicines Agency approval for icotrokinra aiming to transform the plaque psoriasis treatment paradigm",
      "source": "Yahoo",
      "datetime": 1757595360,
      "summary": "Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor.1 Filing based on four Phase 3 studies that met all primary and co-primary endpoints. This unprecedented data package includes head-to-head superiority comparisons versus deucravacitinib,",
      "url": "https://finnhub.io/api/news?id=bbc6db312b4612ae9058b028086613f2d7976c8bc554ffb2c71022261cf371e2"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627547.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000196/xslF345X05/wk-form4_1757627547.xml"
    },
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627315.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000194/xslF345X05/wk-form4_1757627315.xml"
    },
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627206.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000192/xslF345X05/wk-form4_1757627206.xml"
    },
    {
      "form": "8-K",
      "date": "2025-09-09",
      "description": "jnj-20250908.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000190/jnj-20250908.htm"
    },
    {
      "form": "4",
      "date": "2025-09-05",
      "description": "xslF345X05/wk-form4_1757109644.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000186/xslF345X05/wk-form4_1757109644.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}